Adenosine A2A Receptor Functional HEK293 Cell Line

Catalog #
79381
$11,095 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Adenosine A2A receptor (A2aR or ADORA2A) stably expressed in HEK293 cells (NM_000675.5). A2aR is a member of the seven transmembrane G protein-coupled receptor (GPCR) family. The activity of A2aR is mediated by Gαs protein which activates adenylyl cyclase, resulting in the synthesis of intracellular cAMP. The level of cAMP correlates with the level of adenosine. This cell line can be used to measure the EC50 and IC50 values of A2aR agonists or antagonists.

79381 Background

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
Adenosine receptor A2a, ADORA2A, ADORA2
Product Info
Storage and Usage
Citations
Host Cell Line
HEK293, Human Embryonic Kidney, epithelial-like cells, adherent
Supplied As
Each vial contains 2 x 106 cells in 1 ml of cell freezing medium (BPS Bioscience #79796)
Materials Required But Not Supplied

Media Required for Cell Culture

Name Ordering Information
Thaw Medium 1 BPS Bioscience #60187
Growth Medium 1G BPS Bioscience #79544


Materials Required for Cellular Assay

Name Ordering Information
Charcoal stripped fetal bovine serum ThermoFisher #A3382101
IBMX Sigma-Aldrich #I7018
Ro 20-1724 Sigma Aldrich #557502
CGS-21680 hydrochloride hydrate Sigma Aldrich #C141
ZM 241385 Sigma Aldrich #Z0153
cAMP assay kit such as  
cAMP-Gs Dynamic PerkinElmer/Cisbio #62AM4PEB
cAMPGlo kit Promega #V1501
96-well PDL coated white clear-bottom assay plate Corning #354651
Plate reader to read the cAMP assay kit  
Genbank #
NM_000675.5
UniProt #
P29274
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

Adenosine signaling plays an important role in inflammation and the immune response. Many cells in the tumor microenvironment express ectopic CD39 and CD73, leading to the buildup of extracellular adenosine. Engagement of adenosine with the high affinity Adenosine A2A receptor (A2aR) on the surface of T cells, macrophages, NK cells, neutrophils, and dendritic cells causes downregulation of the immune response. Therefore, A2aR is a novel immune checkpoint protein, and blockade of A2aR is being actively investigated as a potential immunotherapy. Several A2aR antagonists have progressed to clinical trials for the treatment of Parkinson’s disease, and preclinical studies have confirmed that blockade of A2aR activation has the ability to markedly enhance anti-tumor immunity. Mice treated with A2aR antagonists, such as ZM241385 or caffeine, show significantly delayed tumor growth, and A2aR knockout mice demonstrate increased tumor rejection. Most promising, A2aR blockade can be used in synergy with the inhibition of other immune checkpoint pathways. Studies show that the combination of A2aR blockade and PD-1 inhibition is more effective than either treatment separately, and A2aR blockade increases the activity of CTLA-4 and TIM-3 inhibition in controlling the growth of CD73+ melanoma.

 

References

1. Leone, R.D., et.al. (2015). Comp. Struct. Biotechnol. J. 13: 265-272
2. Ma, S-R., et al. (2017). Molec. Cancer 16:99
3. Ohta, A., (2016). Front. Immunol. 7:109.
4. Yang et al. (2017) Purinergic Signal. 13(2): 191–201
5. Varela et al. (2017) Neoplasia. 530–536 530.